Moti Ramgopal

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Pedro Cahn, Anton Pozniak, Horacio Mingrone et al. · The Lancet · 2013 · 514 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacotherapy +16

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

David Wyles, Peter Ruane, Mark Sulkowski et al. · New England Journal of Medicine · 2015 · 422 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +17

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Interleukin-7 promotes HIV persistence during antiretroviral therapy

Claire Vandergeeten, Rémi Fromentin, Sandrina DaFonseca et al. · Blood · 2013 · 249 citations · Full text

Life Sciences, Immunology, Infectious Diseases +14